Stock Evaluator: SCHOTT Pharma AG & Co. KGaA (SHTPY)
SCHOTT Pharma AG & Co. KGaA SHTPY
$7.02
0.00
0.00%
September 2, 2026 3:02:39 PM
EST
Volume: 0
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Financial Summary
| Share Statistics | SHTPY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,034.5 | $3,703.9 | 64% |
|
| Shares Out (Mil) | 170.6 | 98.2 | 73% |
|
| Institutional Ownership | na | 89.6% | na |
|
| Float (Mil) | 34.6 | 71.5 | 39% |
|
| Beta | 0.98 | 1.19 | 59% |
|
| Avg Daily Volume (000s) | 0 | 557 | 0% |
|
| Price Change (52-week) |
na | 85.5% | na |
|
| Growth | SHTPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.0% | 7.8% | 62% |
|
| Net Income (5yr) | 13.6% | (11.2%) | 61% |
|
| EPS (5yr) | 13.7% | 2.5% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 61% |
|
| Cash Flow (5yr) | (14.9%) | (15.0%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SHTPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,162 | $810 | 52% |
|
| Net Income (TTM) (Mil) | $156 | ($31) | 65% |
|
| EPS (TTM) | $1.031 | ($0.300) | 61% |
|
| Operating Cash Flow (TTM) (Mil) | $220 | $56 | 60% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $3 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $88 | $264 | 43% |
|
| Enterprise Value (Q1) (Mil) | $4,103 | $3,795 | 59% |
|
| Valuation | SHTPY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.74 | na |
|
| P/E | na | 38.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 5.7 | na |
|
| Ratios | SHTPY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 31.2% | 47.6% | 37% |
|
| Net Margin | 13.4% | (2.6%) | 70% |
|
| ROA | 8.3% | (4.0%) | 83% |
|
| ROE | 14.5% | (7.7%) | 69% |
|
| Liabilities to Assets | 41.1% | 41.1% | 32% |
|
| F-Score | na | 5 | na |
|
SCHOTT Pharma AG & Co. KGaA did not pass any screens on 9/4/2026.
